TCL-416: Updated Clinical Data From the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients With Relapsed/Refractory Cytotoxic T/NK Cell Lymphomas
Year: 2026
Type: conference-abstract
Authors: Swaminathan Iyer, Christina Poh, Jasmine Zain, Christiane Querfeld, John Reneau, Jonathan Brammer, Costas Yannakou, Mengyang Di, Cinzia Pellegrini, Pier Luigi Zinzani, Oleg Akilov, Youn Kim, Michael Khodadoust, Nathan Roberts, Enrica Marchi, Yok Lam Kwong, Ji Hyun Lee, Youngil Koh, Hyeon-Seok Eom, Won Seog Kim, Jake Shortt, Alejandro Gru, Alissa Keegan, Wan-Jen Hong, Ruoshi Shi, Jennifer Richardson, Nenad Tomasevic, H Miles Prince, Steven Horwitz
Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The University of Melbourne, Epworth Hospital, Fred Hutch Cancer Center, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Pittsburgh Medical Center, Stanford University, University of Virginia Cancer Center, Dana-Farber Cancer Institute, University of Hong Kong, Dong-A University, Seoul National University Hospital, National Cancer Center, Samsung Medical Center, Monash University, Columbia University Irving Medical Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204703698